MedTrace Logo

The Effect Of Smoking Status Of The Patient On The Success Of Etanercept Therapy In Psoriasis

NCT02570750 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 183

Last updated 2018-12-20

Study results available
· View outcomes & findings →

Summary

The main purpose of this study is to assess the effect of smoking status on the success of Etanercept therapy in patients with moderate-to-severe psoriasis.

Conditions

  • Chronic Plaque Psoriasis

Interventions

BEHAVIORAL

QUESTIONNAIRE ON SMOKING HABITS

Data on smoking will include the age at which cigarette smoking began and ceased and the average amount smoked daily. Intensity (number of cigarettes smoked per day), duration of smoking (years), and time since cessation (years) will be categorized. Also, the smoking status of the patient prior psoriasis diagnosis will be assessed (smoker or non-smoker and years of smoking prior to psoriasis diagnosis). Smoking habit evaluation: baseline and changes in smoking habit at 12 and 24-weeks follow-up time points.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-07
Primary Completion
2016-12-05
Completion
2016-12-05

Countries

  • Romania

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02570750 on ClinicalTrials.gov